Screener / SEC EDGAR /CIK 0001638833 /10-K filed Mar 2, 2026, compared with Mar 7, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Hospitals

Surgery Partners, Inc. SGRY

Compare with peers Embed
SEC comment letters, last 20 years

5 reviews of SGRY's filings by SEC staff

UPLOAD and CORRESP
Reviews 5 latest letter Jun 26, 2025
Questions asked 46 each answered in the company's own letter
No closing letter 2 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 10 UPLOAD
  2. 2. Questions in them 46 numbered comments
  3. 3. Company replies 11 CORRESP
  4. 4. Reviews closed 3 of 5 closing letter

Half the closed reviews took 27 days or less from the first letter to the closing letter.

Form 10-K

2025-06-26 to 2025-08-07 · 2 questions · 2 letters from the SEC, 2 from the company
Review closed 2025-08-07
Income taxesRevenueSegmentsResults discussion (MD&A)
SEC asked
Organization and Summary of Accounting Policies Revenues, page F-10 1. We note your disclosures that the transaction price for patient service revenues is based on gross charges net of estimated contractual adjustments and implicit price concessions. We further note your disclosure that contractual allowances are recorded at the time of payment for surgical hospitals and the time of billing for ASCs.
Rest of the question

Explain what you mean by contractual adjustments versus contractual allowances and the specific reference to the authoritative literature that supports the timing for recognizing contractual allowances. 9. Income Taxes, page F-26 We note that the valuation allowance against deferred tax assets increased during fiscal year 2024 by $134.6 million, of which $115.4 million is disclosed in the effective tax rate reconciliation as a change in federal valuation allowance, which significantly exceeds the amounts recognized during the two previous fiscal years. Please provide a comprehensive explanation here or within MD&A that provides investors with an understanding of the specific facts and circumstances that led to the 2. significant increase in the valuation allowance. 14. Segment Reporting, page F-31 3. Please tell us whether you believe equity in earnings of unconsolidated affiliates and net income attributable to non-controlling interests represent significant segment expenses determined in accordance with ASC 280-10-50-26A. If so, please provide us with an explanation as to why each line item is a significant segment expense. Alternatively, if these amounts are other segment items as addressed in ASC 280-1050-26B, it appears that these amounts should be aggregated with the other segment expense, net line item into one other segment items line item. Please correspondingly provide a qualitative description of the composition of other segment items in accordance with ASC 280-10-50-26B. 4. With regards to the Corporate and other unallocated expenses in your reconciliation of Adjusted Surgical Facilities EBITDA to consolidated income before income taxes, please revise this presentation to separately disclose revenue and expenses from other business activities that are not considered reportable segments in an “all other” category in accordance with ASC 280-10-50-15 and separately identify and describe all significant reconciling items in accordance with ASC 280-10-50-31. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

SGRY answered
The Company respectfully acknowledges the Staff’s comment and, in response to the Staff’s comment, confirms to the Staff that the terms “contractual adjustments” and “contractual allowances” are used interchangeably by the Company and have the same meaning. We determine the transaction price in accordance with ASC 606, Revenue from Contracts with Customers. Our disclosure was referring to the timing of when contractual adjustments are recorded in our patient accounting systems.
Rest of the answer

However, all revenue transactions are recognized net of estimated contractual adjustments at the time that performance obligations are satisfied, which is generally at the time of service. The Company will revise any discussion of the transaction price in future filings consistent with the following:

The Company determines the transaction price based on gross charges for services provided, net of estimated contractual adjustments and implicit price concessions. The Company estimates its contractual adjustments and implicit price concessions based on contractual agreements, its discount policies and historical experience of cash collections and historical write-offs. The estimated contractual adjustments are recognized at the time of services being performed, with ASCs typically based on contractual agreements and surgical hospitals typically based on historical experience of cash collections and write-offs. Changes in estimated contractual adjustments are recorded in the period of change, with final adjustments, if any, typically at the time of payment.

9. Income Taxes, page F-26

Read in the reply
SEC asked
Income Taxes, page F-26 1. We note your response to comment 2. With reference to your consolidated statements of operations, please help us better understand how you determined that you were in a cumulative 3-year pre-tax income position as of December 31, 2023 but a pre-tax loss position as of December 31, 2024.
Rest of the question

Also confirm that you will provide expanded disclosures to communicate to investors the facts and circumstances for the periods presented that support your accounting in future filings.

SGRY answered
The Company respectfully acknowledges the Staff’s comment and, in response to the Staff’s comment, provides the table below outlining our calculation of the cumulative 3-year pre-tax income position of $14.6 million as of December 31, 2023 (dollars in millions):

2021 2022 2023 Total

Income before income taxes $ 81.2 $ 110.3 $ 135.0 $ 326.5

Less: Net income attributable to non-controlling interests (141.6) (141.6) (147.2) (430.4)

Other comprehensive income (loss) 29.5 107.7 (18.7) 118.5

Total $ (30.9) $ 76.4 $ (30.9) $ 14.6

The table below outlines our calculation of the cumulative
Rest of the answer

3-year pre-tax loss position of $40.7 million as of December 31, 2024 (dollars in millions):

2022 2023 2024 Total

Income before income taxes $ 110.3 $ 135.0 $ 147.1 $ 392.4

Less: Net income attributable to non-controlling interests (141.6) (147.2) (180.6) (469.4)

Other comprehensive income (loss) 107.7 (18.7) (52.7) 36.3

Total $ 76.4 $ (30.9) $ (86.2) $ (40.7)

The Company confirms to the SEC that it will provide expanded disclosures to communicate to investors the facts and circumstances for the periods presented to support our accounting in future filings.

Read in the reply

Also in this review: closing letter, 2025-08-07

Form S-3

2019-12-27 to 2020-01-02 · 2 questions · 2 letters from the SEC, 3 from the company
No closing letter
Legal and contingenciesDerivatives and hedging
SEC asked
We note that your forum selection provision identifies the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation, including any “derivative action.” Please disclose whether this provision applies to actions arising under the Securities Act or Exchange Act.
Rest of the question

In that regard, we note that Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder, and Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. If the provision applies to Securities Act claims, please also revise your prospectus to state that there is uncertainty as to whether a court would enforce such provision and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. If this provision does not apply to actions arising under the Securities Act or Exchange Act, please tell us how you will inform investors in future filings that the provision does not apply to any actions arising under the Securities Act or Exchange Act.

SGRY answered
The Company acknowledges the Staff’s comment and respectfully confirms that the final prospectuses to the Registration Statement will include the revised risk factor disclosure referenced in the Response Letter, which will confirm that the Company’s exclusive forum provision does not apply to actions arising under the Securities Act or the Exchange Act.
Read in the reply
General
SEC asked
We note your response to our prior comment one. Please confirm that you will disclose in the final prospectuses to the registration statement that your exclusive forum provision does not apply to actions arising under the Securities Act or Exchange Act as provided in your response.
SGRY answered
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Surgery Partners, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-235664) (the “Registration Statement”), so that it will be declared effective at 4:30 p.m. Eastern Time on January 6, 2020, or as soon as possible thereafter.
Rest of the answer

The Company hereby authorizes Rachel Phillips, counsel to the Company, to orally modify or withdraw this request for acceleration.

It would be appreciated if, as soon as the Registration Statement is declared effective, you would inform Rachel Phillips of Ropes & Gray LLP, counsel to the Company, at (212) 841-8857.

Read in the reply

Also in this review: company letter, Dec 30, 2019

Form 10-K

2017-08-21 to 2017-09-12 · 4 questions · 1 letter from the SEC, 1 from the company
Review closed 2017-09-12
Non-GAAP measuresSegmentsResults discussion (MD&A)RevenueAcquisitionsLiquidity and cash
Results of Operations, page 58 · Cost of Revenues, pages 59 and 60
SEC asked (1)
Please discuss in greater detail why the underlying expense elements increased, addressing any known trends, risks, or uncertainties that impacted the change in the relationship between costs and revenues, or income from operations, as a result of the acquisitions or otherwise.
Rest of the question

In this regard, we note that cost of revenue, particularly Salaries and benefits, and Professional and medical fees, increased at a much faster rate than revenues year over year for all periods presented. Please refer to Commission Release 33-8350 and Item 303(a)(3)(ii) of Regulation S-K.

SGRY answered
The Company respectfully acknowledges the Staff’s comment and, in response to the Staff’s comment, the Company submits that it will expand its disclosure in future filings to provide additional detail regarding notable increases in the underlying expense elements of cost of revenues.

The Company further notes that the increase in the Company’s cost of revenues during fiscal year 2016 is primarily attributable to the composition of the Company’s acquisitions during such period as compared to that of the prior comparable period.
Rest of the answer

Specifically, the Company’s cost of revenues is affected by the type of practice that is acquired and by the arrangement the Company maintains with the professionals of the acquired practices.

As disclosed on pages 49 and F-17 of the 2016 10-K, during fiscal year 2016, the Company acquired a controlling interest in three anesthesia practices and three surgical facilities, and completed acquisitions of one urgent care facility, nine physician practices and two integrated physician practices (which included three ambulatory surgery centers, a lab and a pharmacy). The Company’s acquisition of a controlling interest in the three anesthesia practices, together with the Company’s acquisition of the nine physician practices and the two integrated physician practices, was the primary driver in the increase in the Company’s cost of revenues, including the disproportionate increase in Salaries and benefits and Professional and medical fees.

In general, anesthesia and physician practices have a lower margin profile than other types of practices included within the Company’s business, which results in overall cost of revenues increasing at a higher rate than the related revenue generated by these practices. In both anesthesia and physician practices, the main driver of these costs relate to the compensation paid to the related anesthesiologists or physicians, which the Company classifies as Salary and benefits, when the Company directly employs the anesthesiologist or physician, or Professional and medical fees, when the Company otherwise contracts with the related anesthesiologist or physician. Given the volume of anesthesia and physician practice acquisitions completed during fiscal year 2016 as compared to the prior comparable period, these classifications resulted in the Salary and benefits and Professional and medical fees increasing at a higher rate than the other line items included within cost of revenues over this period.

Read in the reply
In its next report

First report after the company's reply of Sep 5, 2017: 10-Q filed Nov 9, 2017 ↗, against the 10-Q filed Aug 9, 2017 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

EBITDA, Adjusted EBITDA and Credit Agreement EBITDA, pages 63-66
SEC asked (2)
Since you disclose EBITDA, Adjusted EBITDA and Credit Agreement EBITDA as measures of liquidity, please reconcile these measures to cash flows from operating activities, which is the nearest comparable measure of your Company’s liquidity under GAAP. Notes to Consolidated Financial Statements 15. Segment Reporting, page F-36
SGRY answered
The Company respectfully acknowledges the Staff’s comment and, in response to the Staff’s comment, the Company will expand its disclosure in future filings to reconcile EBITDA, Adjusted EBITDA and Credit Agreement EBITDA to net cash provided by operating activities. The Company will additionally expand this disclosure to present the three major categories of the statement of cash flows.

Notes to Consolidated Financial Statements

15. Segment Reporting, page F-36
Read in the reply
In its next report

First report after the company's reply of Sep 5, 2017: 10-Q filed Nov 9, 2017 ↗, against the 10-Q filed Aug 9, 2017 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

EBITDA, Adjusted EBITDA and Credit Agreement EBITDA, pages 63-66
SEC asked (3)
We note that your measure of segment profit is Segment Adjusted EBITDA. Accordingly, please delete your presentation of the non GAAP measure “Total Adjusted EBITDA” and accompanying explanatory footnotes.
SGRY answered
The Company respectfully acknowledges the Staff’s comment and, in response to the Staff’s comment, the Company will revise its disclosure of each reportable segments’ measure of profit or loss, Segment Adjusted EBITDA, in future filings to delete the presentation of the non-GAAP measure “Total Adjusted EBITDA” and accompanying explanatory footnotes.
Read in the reply
In its next report

First report after the company's reply of Sep 5, 2017: 10-Q filed Nov 9, 2017 ↗, against the 10-Q filed Aug 9, 2017 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

EBITDA, Adjusted EBITDA and Credit Agreement EBITDA, pages 63-66
SEC asked (4)
Please provide a reconciliation of the total of your reportable segments’ measure of profit or loss, Segment Adjusted EBITDA, to your consolidated income before taxes. Refer to ASC 280-10-50-30(b). In this regard, please conform your presentation of Segment Adjusted EBITDA in Management’s Discussion and Analysis of Financial Condition and Results of Operations on page 53 in accordance with this comment.
SGRY answered
The Company respectfully acknowledges the Staff’s comment and, in response to the Staff’s comment, in addition to revising its disclosure regarding segment profits or loss in future filings to delete the presentation of the non-GAAP measure “Total Adjusted EBITDA” and accompanying explanatory footnotes as stated in the Company’s response to Comment 3 above, the Company will further revise its disclosure to include a reconciliation of Segment Adjusted EBITDA to Income (loss) before income taxes.
Rest of the answer

The Company will adjust the presentation of Segment Adjusted EBITDA in Management’s Discussion and Analysis of Financial Condition and Results of Operations in accordance with this revision in future filings.

The Company hereby acknowledges that (i) it is responsible for the adequacy and accuracy of the disclosure in the filing; (ii) Staff comments or changes to disclosure in response to Staff comments do not foreclose the SEC from taking any action with respect to the filings; and (iii) it is the Staff’s view that the Company may not assert Staff comments as a defense in any proceeding initiated by the SEC or any person under the federal securities laws of the United States.

Read in the reply
In its next report

First report after the company's reply of Sep 5, 2017: 10-Q filed Nov 9, 2017 ↗, against the 10-Q filed Aug 9, 2017 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2017-09-12

Form 10-K

2016-04-14 to 2016-05-11 · 2 questions · 1 letter from the SEC, 1 from the company
Review closed 2016-05-11
Income taxes
Financial Statements · Note 10. Income Taxes and Tax Receivables Agreement on page F-26
SEC asked (1)
We note that you entered into a Tax Receivable Agreement (TRA) with your pre-IPO shareholders as part of the September 30, 2015 Reorganization. Tell us your consideration of ASC 740-20-45-11g and why you accounted for your TRA obligations as a period expense in the year ended December 31, 2015 rather than equity.
SGRY answered
The Company’s accounting for the TRA liability is to record its best estimate of the obligation at the end of each reporting period. The estimate for the TRA liability is impacted by the Company’s determination of whether the related deferred tax assets are expected to be realized in the future. As noted in the Staff’s comment, the Reorganization occurred on September 30, 2015. At that time, valuation allowances were recorded which fully reserved the deferred tax assets (i.e., net operating losses

(“NOLs”) and other associated tax attributes) to which the TRA relates.
Rest of the answer

In that regard, realization of those deferred tax assets was not considered more likely than not, and, therefore, it was the Company’s best estimate that there were no amounts expected to be paid under the TRA at that time. Accordingly, no accrual for a TRA liability was recorded at September 30, 2015, the date of the Reorganization. Had a TRA liability been recorded at the date of Reorganization, such would have been recorded through equity. While no accrual was recorded at September 30, 2015, the Company, in its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2015 filed with the SEC on November 13, 2015, appropriately disclosed the existence of the TRA and the potential amount estimated to be payable if the related deferred tax assets were ultimately realized.

At December 31, 2015, as disclosed in the Company’s 2015 10-K, based on an evaluation of all positive and negative evidence pertaining to the realization of the deferred tax assets, the Company released substantially all of its valuation allowances, including those valuation allowances previously recorded against the deferred tax assets to which the TRA relates. With the release of those valuation allowances, the Company recorded the TRA liability as the payments to the pre-IPO shareholders were now expected to be paid given the expected realization of the related deferred tax assets. Recognition of the TRA obligation subsequent to the IPO would represent an element of the Company’s operating results and not the effect of a change in arrangements between the Company and its prior owners. Because the recording of the TRA liability occurred subsequent to the Reorganization, such change in estimate was appropriately recorded as a period expense, instead of through equity. This accounting treatment is consistent with the guidance in ASC 740-20-45-11(g) which states, “All changes in the tax bases of assets and liabilities caused by transactions among or with shareholders shall be included in equity including the effect of valuation allowances initially required upon recognition of any related deferred tax assets. Changes in valuation allowances occurring in subsequent periods shall be included in the income statement.” As discussed above, there were no changes in tax bases of assets and liabilities at September 30, 2015, the date of Reorganization, due to the full valuation allowance recorded at that time. However, consistent with the guidance in ASC 740-20-45-11(g) described above, the subsequent change to tax bases recorded at December 31, 2015 were recorded through the statement of operations.

Read in the reply
In its next report

First report after the company's reply of Apr 25, 2016: 10-Q filed May 6, 2016 ↗, against the 10-Q filed Nov 13, 2015 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Financial Statements · Note 10. Income Taxes and Tax Receivables Agreement on page F-26
SEC asked (2)
Further, we note from the table on page F-28 that you have recorded a recorded a disproportionately small deferred tax asset of $2.75 million for this TRA liability. Please tell us how you determined this $2.75 million deferred tax asset.
SGRY answered
The TRA that the Company entered into relates to historic tax attributes that existed at the date of the Reorganization which carried over to the post-Reorganization company. The TRA requires the Company to pay out to the pre-IPO shareholders an amount equal to 85% of the amount of tax savings realized (or in certain cases deemed realized) by the Company as a result of the Company’s pre-IPO NOLs and certain other tax attributes, plus accrued and imputed interest.
Rest of the answer

Payments pursuant to the TRA are intended to be treated for tax purposes as contingent boot in a nontaxable transaction, except to the extent treated as payments of imputed interest. These payouts will occur over time such that a portion of the deferred payouts will be treated as imputed interest for tax purposes. The deferred tax asset that was recorded at December 31, 2015 represents the portion of the TRA liability that represents expected imputed interest for tax purposes. This portion of the TRA that represents an expected future interest deduction for tax purposes was estimated to be approximately $7.26 million, which resulted in a deferred tax asset of $2.75 million. The NOLs and other associated tax attributes are reflected separately within the deferred tax schedule as NOLs and Capital Loss Carryforwards, among others. While realization of these tax attributes creates a payout obligation under the TRA, they did not originate with the recording of the TRA.

The Company hereby acknowledges that (i) it is responsible for the adequacy and accuracy of the disclosure in the filing; (ii) Staff comments or changes to disclosure in response to Staff comments do not foreclose the SEC from taking any action with respect to the filings; and (iii) it is the Staff’s view that the Company may not assert Staff comments as a defense in any proceeding initiated by the SEC or any person under the federal securities laws of the United States.

Read in the reply
In its next report

First report after the company's reply of Apr 25, 2016: 10-Q filed May 6, 2016 ↗, against the 10-Q filed Nov 13, 2015 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2016-05-11

Form S-1

2015-05-19 to 2015-09-29 · 36 questions · 4 letters from the SEC, 4 from the company
No closing letter
Results discussion (MD&A)RevenueCritical estimatesLiquidity and cashLegal and contingenciesDebtLeasesExecutive payRisk factors
Market and Other Industry Data, page ii
SEC asked (1)
We note your statements, “We have not independently verified any of the data from third-party sources nor have we ascertained the underlying economic assumptions relied upon therein. Similarly, internal surveys, industry forecasts and market research which we believe to be reliable based upon our management’s knowledge of the industry, have not been independently verified.” It is not appropriate to infer that you
Rest of the question

are not liable for statements included in your registration statement. Please revise your disclosure to delete the statements referenced above.

SGRY answered

No numbered answer found in the reply. Read the reply ↗

Prospectus Summary · Patients, page 3
SEC asked (2)
Please quantify how many patients participated in your internal surveys conducted in 2014, the degree of participation and how the patient satisfaction rate is measured allowing you to achieve a 94% patient satisfaction rate.
SGRY answered

No numbered answer found in the reply. Read the reply ↗

Prospectus Summary · Patients, page 3
SEC asked (3)
Please revise your disclosure to quantify the patient satisfaction rate industry average and describe how this rate is measured.
SGRY answered

No numbered answer found in the reply. Read the reply ↗

Prospectus Summary · Patients, page 3
SEC asked (4)
You state that according to internal survey’s conducted in 2014, your patients have expressed a 94% patient satisfaction rate, which exceeds the industry average. Please expand your disclosure to describe these surveys and whether they are the same as ones used to gather industry data.
Rest of the question

If not, please explain why it is appropriate to compare a satisfaction rate achieved from your own internal surveys to an industry satisfaction rate that was achieved using different surveys.

SGRY answered

No numbered answer found in the reply. Read the reply ↗

Prospectus Summary · Patients, page 3
SEC asked (5)
Please expand your disclosure to briefly describe CMS’ Ambulatory Surgical Center Quality Reporting program’s six key core ASC quality measures when you first refer to them in this section.
SGRY answered

No numbered answer found in the reply. Read the reply ↗

Prospectus Summary · Patients, page 3
SEC asked (6)
We note the statement that surgeries in your facilities are less expensive than the same surgeries performed in a hospital outpatient department. Please expand the discussion to clarify whether you are referring solely to the cost of the use of the facility or whether the comparison includes surgeon fees, anesthesiology fees, etc.
Rest of the question

In addition, please clarify whether your facility charge is the same whether the surgery is performed in one of your ASCs or surgical hospitals. We may have additional comments.

SGRY answered

No numbered answer found in the reply. Read the reply ↗

Summary Consolidated Historical and Pro Forma Condensed Combined Financial…, page 15
SEC asked (7)
Please tell us how you concluded it was appropriate to present pro forma cash flow information. Tell us the nature and amount of the adjustments that were used to calculate the pro forma cash flow amounts.
SGRY answered

No numbered answer found in the reply. Read the reply ↗

Risks Related to Our Business and Industry · We may become involved in litigation which could negatively impact the value…, page 27
SEC asked (8)
We note your disclosure that in certain instances former employees have brought claims against you. If you have had actions brought against you which caused a reduction in your revenues resulting in a material adverse effect on your business in the recent past, please discuss the claim and the consequences of the claim.
SGRY answered

No numbered answer found in the reply. Read the reply ↗

Certain of our partnership and operating agreements contain termination dates…, page 30
SEC asked (9)
We note that certain of your limited partnership, general partnership and limited liability company agreements have termination dates by which the agreement expires by its terms. Please expand your disclosure to quantify the number of agreements which will expire within the next three years and whether the expiration of such agreement if not renewed will have a material adverse effect on your business.
SGRY answered

No numbered answer found in the reply. Read the reply ↗

Our variable rate indebtedness subject us to interest rate risk, which could cause…, page 36
SEC asked (10)
Please expand your disclosure in this risk to provide the amounts currently outstanding under your Term Loans and Revolving Facility and to describe the interest rates to which your loans are subject.
SGRY answered

No numbered answer found in the reply. Read the reply ↗

Use of Proceeds, page 58
SEC asked (11)
Please revise your disclosure to provide the amount of proceeds that will be used to repay a portion of the Second Lien Term Loan. Please make confirming revisions in the other areas of your prospectus where you provide a discussion of how proceeds from this offering will be used.
SGRY answered

No numbered answer found in the reply. Read the reply ↗

Capitalization, page 60
SEC asked (12)
Please separate the line item cash and cash equivalents with a double underline to clearly separate it from your capitalization. Remove the line item ‘Total liabilities and stockholders’ equity (deficit)’ as not all liabilities from the balance sheet are included in the capitalization table.
Rest of the question

Please explain why you have not populated the historical amounts for stockholders’ equity (deficit), non-controlling interests and total historical capitalization.

SGRY answered

No numbered answer found in the reply. Read the reply ↗

Long Term Debt · Revolver, page 85
SEC asked (13)
Please file the credit agreement that governs the Revolver as an exhibit.
SGRY answered

No numbered answer found in the reply. Read the reply ↗

Business · One of the Nation’s Largest and Fastest Growing Surgical Services Platform…, page 95
SEC asked (14)
In this section where you first discuss Certificate of Need (“CON”) laws and on page 116 where you provide further discussion of these laws, please explain why CON laws only apply to your competitors and present a competitive advantage to existing operators such as yourself.
SGRY answered

No numbered answer found in the reply. Read the reply ↗

Our Operations Overview · General, page 105
SEC asked (15)
We note your typical leases are for 10 years with two five year renewal options. Please quantify the number of leases you have for your facilities and the number of those leases which are set to expire within the next three years.
SGRY answered

No numbered answer found in the reply. Read the reply ↗

Competition, page 111
SEC asked (16)
Please disclose where you rank among the largest ASC operators listed in this section.
SGRY answered

No numbered answer found in the reply. Read the reply ↗

Executive Compensation · Annual Cash Bonuses, page 137
SEC asked (17)
We note that Mr. Doyle, Ms. Sparks and Mr. Crysel were eligible to earn target cash bonuses based on the achievement of specified EBITDA targets for the company as set forth in their employment agreements. Please expand your disclosure to describe these EBITDA targets in this section of your prospectus.
SGRY answered

No numbered answer found in the reply. Read the reply ↗

Incentive Plans, page 140
SEC asked (18)
We note that in connection with this offering, you intend to adopt an equity incentive plan and a cash incentive plan. Please expand your disclosure to describe these plans. Also, please file the cash incentive plan as an exhibit.
SGRY answered

No numbered answer found in the reply. Read the reply ↗

Principal Stockholders, page 148
SEC asked (19)
Please revise your beneficial ownership table so that it is as of the most recent date practicable.
SGRY answered

No numbered answer found in the reply. Read the reply ↗

Index to Consolidated Financial Statements · General
SEC asked (20)
We note your disclosure on pages 15 and 66 that the prospectus does not include financial statements of Surgery Partners, Inc. as it has been incorporated solely for the purpose of effecting the offering and currently holds no material assets and does not engage in any operations. However, we do not believe this provides a sufficient basis to omit the audited financial statements of the registrant.
Rest of the question

Please provide audited financial statements of the registrant Surgery Partners, Inc. as required by Rule 3-01(a) of Regulation S-X, or tell us why you believe such financial statements are not required.

SGRY answered

No numbered answer found in the reply. Read the reply ↗

Consolidated Statements of Operations, page F-5
SEC asked (21)
You have disclosed on page F-18 that the company does not believe earnings per share to be a meaningful presentation in the financial statements. Therefore please clarify when the line items for net income (loss) per share and weighted average common shares outstanding will be populated in the statement of operations and what they will represent.
Rest of the question

Please clarify how the 1,000 shares of outstanding common stock shown in the statement of stockholders’ equity will be considered in these calculations.

SGRY answered

No numbered answer found in the reply. Read the reply ↗

Consolidated Statements of Stockholders’ Equity, page F-7
SEC asked (22)
It appears based on your disclosure on page F-36 that all compensation expense relates to B-Units. Therefore, please explain why the line items in 2012 and 2013 are labeled stock-based compensation and the line item for 2014 is unit-based compensation. Notes to Consolidated Financial Statements 12. Unit-Based Compensation, page F-36
SGRY answered

No numbered answer found in the reply. Read the reply ↗

Consolidated Statements of Stockholders’ Equity, page F-7
SEC asked (23)
You disclose on page F-17 that all option pricing models require the input of highly subjective assumptions including the expected stock price volatility and the expected exercise patterns of the option holders. Please expand your disclosures to describe the specific methods used to determine fair value of the units. Please tell us your consideration of including this as a critical accounting policy.
SGRY answered

No numbered answer found in the reply. Read the reply ↗

Consolidated Statements of Stockholders’ Equity, page F-7
SEC asked (24)
We may have additional comments on your accounting for equity issuances including unit-based compensation and beneficial conversion features. Once you have an estimated offering price, please provide us an analysis explaining the reasons for the differences between recent valuations of your units leading up to the IPO and the estimated offering price.
SGRY answered
The Company supplementally advises the Staff that, based on discussions with the Company’s Board of Directors and input provided by the underwriters, the Company currently anticipates that the price range for this offering is expected to be within the range of

$[*

* *] to $[* * *] per share, with, assuming an offering price at the midpoint of the range, approximately [* * *] shares of common stock offered to the public in connection with the offering (or approximately [* * *] shares if the underwriters fully exercise their option to purchase additional shares), representing approximately [*
Rest of the answer

* *]% of the voting power and economic interest in the Company (or approximately [* * *]% if the underwriters exercise in full their option to purchase additional shares of common stock). In arriving at this preliminary price range, the Company and the underwriters considered several factors, including the Company’s history and prospects and those of the industry in which the Company competes; the current general condition of the securities markets and, in particular, the recent volatility of such markets; the recent market prices of the common stock of generally comparable companies; and preliminary discussions between the Company and the underwriters regarding potential valuations of the Company as a public company. As discussed with the Staff, we have not provided further information on the valuation of the Class B Units in Surgery Center

Holdings, LLC issued prior to the Company’s initial public offering as the legal structure of the Company prior to its initial public offering is not consistent with its structure following the initial public offering, and therefore those units did not represent interests in common stock of the Company. As described in the Registration Statement, following the initial public offering, the Company intends to adopt an equity incentive plan for the issuance of awards that represent interests in common stock of the Company.

If you require additional information, please feel free to contact Carl Marcellino of our offices at

(212) 841-0623.

Best regards,

/s/ Carl Marcellino

Carl Marcellino (Ropes & Gray LLP) cc:

Read in the reply
Other Comments
SEC asked (25)
We note that there are a number of additional exhibits that still need to be filed. Please provide these exhibits as promptly as possible. Please note that we may have comments on these materials once they are provided.
SGRY answered

No numbered answer found in the reply. Read the reply ↗

Other Comments
SEC asked (26)
Please confirm that the graphics included in your registration statement are the only graphics you will use in your prospectus. If those are not the only graphics, please provide any additional graphics prior to their use for our review.
SGRY answered

No numbered answer found in the reply. Read the reply ↗

Other Comments
SEC asked (27)
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
Rest of the question

If you intend to respond to these comments with an amended draft registration statement, please submit it and any associated correspondence in accordance with the guidance we provide in the Division’s October 11, 2012 announcement on the SEC website at http://www.sec.gov/divisions/corpfin/cfannouncements/drsfilingprocedures101512.htm. Please keep in mind that we may publicly post filing review correspondence in accordance with our December 1, 2011 policy (http://www.sec.gov/divisions/corpfin/cfannouncements/edgarcorrespondence.htm). If you intend to use Rule 83 (17 CFR 200.83) to request confidential treatment of information in the correspondence you submit on EDGAR, please properly mark that information in each of your confidential submissions to us so we do not repeat or refer to that information in our comment letters to you.

SGRY answered

No numbered answer found in the reply. Read the reply ↗

SEC letter of Jul 6, 2015 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Prospectus Summary · Patients, page 3
SEC asked (1)
We note your response to our prior comment 2 and your revised disclosure in response to our comment. Please expand your disclosure to describe how the patient satisfaction rate is measured allowing you to achieve a 94% patient satisfaction rate.
SGRY answered

No reply letter found.

Prospectus Summary · Patients, page 3
SEC asked (2)
We note your response to our prior comment 4. However, it does not appear that you have included a description of your internal surveys in your prospectus as stated in your response. In addition, we note that while you have deleted the comparison between your patient satisfaction rate and the industry average rate, you now state, “On average, our facilities exceeded industry averages for each of Centers for Medicare
Rest of the question

and Medicaid Services, or CMS, 2014 Ambulatory Surgical Center Quality Reporting (ASCQR) program’s five key core ASC quality measures…” Please expand your disclosure to describe your internal surveys and whether they are the same ones used to gather data for industry averages for the CMS 2014 ASQR programs five key core ASC quality measures. If not, please explain why it is appropriate to state that your facilities exceeded measures.

SGRY answered

No reply letter found.

Annual Cash Bonuses, page 141
SEC asked (3)
We note your response to our prior comment 17 and expanded disclosure in response to our comment. Please revise your disclosure to provide the EBITDA targets on which Mr. Doyle’s, Mr. Spark’s and Mr Crysel’s bonuses were based.
SGRY answered

No reply letter found.

Principal Stockholders, page 152
SEC asked (4)
We note that in response to our prior comment 19, you have revised your beneficial ownership table to provide data as of May 1, 2015. Please revise your table to be as of the most recent practicable date not to exceed two weeks from the filing date of your registration statement. Surgery Center Holdings, Inc.
SGRY answered

No reply letter found.

Consolidated Statements of Operations, page F-9
SEC asked (5)
Please refer to your response to comment 21. Since the reorganization will not occur until immediately prior to the consummation of the offering, it is still not clear why earnings per share are not presented in the historical financial statements. Elsewhere in the filing you present historical financial information and then “as adjusted” financial information that gives effect to the reorganization.
Rest of the question

Therefore, please revise your statements of operations to include the historical earnings per share and weighted average common shares outstanding. Notes to Consolidated Financial Statements 2. Significant Accounting Policies,

SGRY answered

No reply letter found.

Unit-Based Compensation, page F-21
SEC asked (6)
Please refer to your response to comment 23. You acknowledge that unit-based compensation is a critical accounting policy. Therefore, please explain why this is not included in the critical accounting policies section of MD&A beginning on page 76.
Rest of the question

Please revise your disclosure to clarify that these estimates are highly complex and subjective and that these estimates will not be necessary to determine fair value once the underlying shares begin trading.

SGRY answered

No reply letter found.

SEC letter of Aug 26, 2015 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Management’s Discussion and Analysis of Financial Condition and Result of Operations · Results of Operations, page 84
SEC asked (1)
It appears the operating income as a percentage of revenues for the year ended December 31, 2014 should be 12.6% rather than the 9.2% disclosed in the table. Please revise or explain why you believe a revision is not necessary.
SGRY answered

No reply letter found.

Exhibit 23.3
SEC asked (2)
Please file a revised consent that references the correct date for Note 2. The consent states that the date for Note 2 is July 31, 2015 but the audit report states that the date is August 3, 2015.
SGRY answered

No reply letter found.

Risk Factors, page 21
SEC asked
We note that your amended and restated certificate of incorporation includes an exclusive forum provision as Article IX naming the Court of Chancery for the State of Delaware as the exclusive forum for the actions described in the Article.
Rest of the question

Under an appropriately titled risk factor, please describe the exclusive forum provision and the types of actions to which it relates and disclose that such a provisions may limit a shareholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with the company and its directors, officers or other employees and may discourage lawsuits with respect to such claims.

SGRY answered
The Company has revised the Registration Statement to add an appropriately titled risk factor describing the exclusive forum provision and the types of actions to which it relates and disclosing that such a provision may limit a shareholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with the Company and its directors, officers or other employees and may discourage lawsuits with respect to such claims. Please see the revisions on page 57.
Read in the reply

Also in this review: company letter, Sep 29, 2015, company letter, Sep 29, 2015

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 24 letters filed since 2015-05-20. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SGRY/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.